Ascletis has wooed another top pharma exec from the US to China as it gets ready to show that its R&D team has what it takes to come up with some first-in-class drugs.
In taking up the CSO role Handan He is leaving behind a 22-year stint at Novartis, where her last title was global head of computational, biopharmaceutics and translational PK/PD.
Her arrival marks another big get for CEO Jinzi Wu, who earlier this year recruited Merck?s top drug developer in China as Ascletis? CMO. But health and family concerns cut Zhengqing Li?s tenure short, forcing him to depart af